DFS by treatment regimen. The DFS for the 309 randomized patients did not differ by postremission treatment arm (log-rank test, P = .66). The medians were 1.1 years (95% CI, 0.9-1.7 years) for those assigned to receive 3 courses of HiDAC (solid line) and 1.0 year (95% CI, 0.9-1.3 years) for those assigned to receive sequential MCT (dotted line). Approximately 35% (95% CI, 27%-42%) survived disease free for at least 5 years after randomization to HiDAC and 30% (95% CI, 23%-37%) after randomization to MCT.